top 10 innovations 2012, genetics & genomics, immunology
Pulling It All Together
Pulling It All Together
Kate Yandell | Apr 1, 2016
Systems-biology approaches offer new strategies for finding hard-to-identify drug targets for cancer.
Guts and Glory
Guts and Glory
Anna Azvolinsky | Apr 1, 2016
An open mind and collaborative spirit have taken Hans Clevers on a journey from medicine to developmental biology, gastroenterology, cancer, and stem cells.
Death in the Dust
Death in the Dust
The Scientist Staff | Apr 1, 2016
Follow Michele Carbone as he tracks down the genetic and environmental drivers of mesothelioma and other cancers.
Minimal Genome Created
Minimal Genome Created
Ruth Williams | Mar 24, 2016
Scientists build a living cellular organism with a genome smaller than any known in nature.
Former Affymetrix Employees Fail to Stop Thermo Fisher Takeover
Former Affymetrix Employees Fail to Stop Thermo Fisher Takeover
Bob Grant | Mar 22, 2016
Their $1.5 billion bid, which topped Thermo Fisher Scientific’s $1.3 billion offer for the genetic analysis company, was rejected.
Origins of Dysentery
Origins of Dysentery
Bob Grant | Mar 22, 2016
A new genomic analysis reveals that the pathogen responsible for the gastrointestinal disease likely originated in Europe and hitched a ride to new lands with settlers.
CRISPR Can Tag RNA
CRISPR Can Tag RNA
Kerry Grens | Mar 21, 2016
Modifications to the DNA-slicing program allow for monitoring the movement of messenger RNA.
Study: Genetic Tests Don’t Change Behavior
Study: Genetic Tests Don’t Change Behavior
Jef Akst | Mar 17, 2016
Knowing one’s genetic risk for particular diseases doesn’t encourage behavior modifications, according to a study.
Clock Reset on Denisovan-Neanderthal Split
Clock Reset on Denisovan-Neanderthal Split
Kerry Grens | Mar 14, 2016
Nuclear DNA from 430,000-year-old specimens indicates that Neanderthals had already diverged from their ancient-human predecessors.
CRISPRi-Controlled Gene Expression
CRISPRi-Controlled Gene Expression
Jef Akst | Mar 10, 2016
A variation of the gene-editing technique can more precisely and efficiently downregulate the expression of target genes than traditional CRISPR/Cas9.